Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRG001
- Development stage
- Phase 1
- Lead developer
- MedRegen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Topical
01
Overview
MRG001 is an investigational **CD20-directed antibody-drug conjugate** developed by Hangzhou Miracogen for relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma. It comprises a chimeric anti-CD20 monoclonal antibody linked through a protease-cleavable valine-citrulline linker to the microtubule-disrupting payload monomethyl auristatin E. Following CD20 binding and cellular internalization, intracellular linker cleavage releases the cytotoxic payload, resulting in tubulin disruption, mitotic arrest, and tumor-cell death. MRG001 has been evaluated in a first-in-human Phase 1 study in CD20-positive relapsed or refractory B-cell non-Hodgkin lymphoma and is being studied in Phase 2 combination treatment with orelabrutinib for relapsed or refractory diffuse large B-cell lymphoma.
- Other names
- MRG-001MRG001MRG 001
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD20 (B-lymphocyte antigen CD20)CXCR4 (C-X-C motif chemokine receptor 4)CN (Calcineurin)
Beyond the preview
Go deeper on MRG001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRG001.